International workshop on immune tolerance induction

Consensus recommendations

D. M. DiMichele, W. K. Hoots, S. W. Pipe, G. E. Rivard, E. Santagostino

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of scientific evidence to guide therapeutic decision-making. In an effort to provide direction for physicians and hemophilia treatment center staff members, an international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophilia A and hemophilia B. These recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.

Original languageEnglish
Pages (from-to)1-22
Number of pages22
JournalHaemophilia
Volume13
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Immune Tolerance
Hemophilia A
Consensus
Education
Hemophilia B
Decision Making
Pharmacokinetics
Physicians
Therapeutics

Keywords

  • Factor IX
  • Factor VIII
  • Hemophilia A
  • Hemophilia B
  • Immune tolerance induction
  • Inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

International workshop on immune tolerance induction : Consensus recommendations. / DiMichele, D. M.; Hoots, W. K.; Pipe, S. W.; Rivard, G. E.; Santagostino, E.

In: Haemophilia, Vol. 13, No. SUPPL. 1, 07.2007, p. 1-22.

Research output: Contribution to journalArticle

DiMichele, D. M. ; Hoots, W. K. ; Pipe, S. W. ; Rivard, G. E. ; Santagostino, E. / International workshop on immune tolerance induction : Consensus recommendations. In: Haemophilia. 2007 ; Vol. 13, No. SUPPL. 1. pp. 1-22.
@article{7ea6736eb3504ddf999bef9cac3f6c71,
title = "International workshop on immune tolerance induction: Consensus recommendations",
abstract = "Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of scientific evidence to guide therapeutic decision-making. In an effort to provide direction for physicians and hemophilia treatment center staff members, an international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophilia A and hemophilia B. These recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.",
keywords = "Factor IX, Factor VIII, Hemophilia A, Hemophilia B, Immune tolerance induction, Inhibitors",
author = "DiMichele, {D. M.} and Hoots, {W. K.} and Pipe, {S. W.} and Rivard, {G. E.} and E. Santagostino",
year = "2007",
month = "7",
doi = "10.1111/j.1365-2516.2007.01497.x",
language = "English",
volume = "13",
pages = "1--22",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - International workshop on immune tolerance induction

T2 - Consensus recommendations

AU - DiMichele, D. M.

AU - Hoots, W. K.

AU - Pipe, S. W.

AU - Rivard, G. E.

AU - Santagostino, E.

PY - 2007/7

Y1 - 2007/7

N2 - Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of scientific evidence to guide therapeutic decision-making. In an effort to provide direction for physicians and hemophilia treatment center staff members, an international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophilia A and hemophilia B. These recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.

AB - Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of scientific evidence to guide therapeutic decision-making. In an effort to provide direction for physicians and hemophilia treatment center staff members, an international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophilia A and hemophilia B. These recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.

KW - Factor IX

KW - Factor VIII

KW - Hemophilia A

KW - Hemophilia B

KW - Immune tolerance induction

KW - Inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34347360724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347360724&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2007.01497.x

DO - 10.1111/j.1365-2516.2007.01497.x

M3 - Article

VL - 13

SP - 1

EP - 22

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - SUPPL. 1

ER -